Argenx SE
ARGX
Rangering i aksjer
#443
argenx SE, a biotechnology company established in Amsterdam, the Netherlands,... argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.
Aksjekurs
$878.61
Markedsverdi
$55.07B
Endring (1 dag)
6.42%
Endring (1 år)
3.43%
Land
NL
Handel Argenx SE (ARGX)
Kategori
Healthcare
Inntekter for Argenx SE (ARGX)
Inntekter i Jun 2026 TTM: $1.95B
Ifølge Argenx SE sine nyeste økonomiske rapporter er selskapets nåværende resultat $1.95B. I 2023 hadde selskapet et resultat på $-304.50M, en økning sammenlignet med resultatet i 2022, som var $-729.31M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Argenx SE fra 2011 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $1.95B | 2,190.03% |
| 2024 | $85.18M | -127.97% |
| 2023 | $-304.50M | -58.25% |
| 2022 | $-729.31M | 82.45% |
| 2021 | $-399.74M | -45.78% |
| 2020 | $-737.24M | 273.52% |
| 2019 | $-197.38M | 128.03% |
| 2018 | $-86.56M | 118.82% |
| 2017 | $-39.56M | 67.25% |
| 2016 | $-23.65M | 30.12% |
| 2015 | $-18.18M | 19.79% |
| 2014 | $-15.18M | 30.35% |
| 2013 | $-11.64M | -31.19% |
| 2012 | $-16.92M | 191.01% |
| 2011 | $-5.81M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $5.27B | 170.42% |
US
|
|
| $-3.09B | -258.25% |
US
|
|
| $-4.02B | -305.89% |
AU
|
|
| - | - |
CH
|
|
| $3.01B | 54.09% |
BE
|
